Novel risk score model for non-proliferative diabetic retinopathy based on untargeted metabolomics of venous blood

Front Endocrinol (Lausanne). 2023 Aug 21:14:1180415. doi: 10.3389/fendo.2023.1180415. eCollection 2023.

Abstract

Background and purpose: Nonproliferative diabetic retinopathy (NPDR) occurs in the early stages of Diabetic retinopathy (DR), and the study of its metabolic markers will help to prevent DR. Hence, we aimed to establish a risk score based on multiple metabolites through untargeted metabolomic analysis of venous blood from NPDR patients and diabetic non-DR patients.

Experimental approach: Untargeted metabolomics of venous blood samples from patients with NPDR, diabetes melitus without DR were performed using high-performance liquid chromatography-mass spectrometry.

Results: Detailed metabolomic evaluation showed distinct clusters of metabolites in plasma samples from patients with NPDR and diabetic non-DR patients. NPDR patients had significantly higher levels of phenylacetylglycine, L-aspartic acid, tiglylglycine, and 3-sulfinato-L-alaninate, and lower level of indolelactic acid, threonic acid, L-arginine (Arg), and 4-dodecylbenzenesulfonic acid compared to control. The expression profiles of these eight NPDR risk-related characteristic metabolites were analyzed using Cox regression to establish a risk score model. Subsequently, univariate and multivariate Cox regression analyses were used to determine that this risk score model was a predictor of independent prognosis for NPDR.

Conclusions: Untargeted metabolome analysis of blood metabolites revealed unreported metabolic alterations in NPDR patients compared with those in diabetic non-DR patients or MH. In the venous blood, we identified depleted metabolites thA and Arg, indicating that they might play a role in NPDR development.

Keywords: diabetic retinopathy (DR); nonproliferative diabetic retinopathy (NPDR); risk score; untargeted metabolomics; venous blood.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Arginine
  • Diabetes Mellitus*
  • Diabetic Retinopathy*
  • Humans
  • Metabolome
  • Metabolomics
  • Risk Factors

Substances

  • Arginine

Grants and funding

This work was supported by grants from the National Natural Science Foundation of China (82000824 to SY, 82170842 to ZL, and 82171556 to LK), the Natural Science Foundation of Shenzhen City, China to ZL (No. KCXFZ20201221173600001), the National Key Research and Development Program of China (2018YFC2001100), and the Science and Technology Project of Zengcheng District, Guangzhou, No.2021-050.